Mike Botta

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

Almost a year since the start of the pandemic, it’s clear a new medical vision is taking shape—one focused on serving patients now, solving procedural issues later.